Corcept Therapeutics
miricorilant
metabolic dysfunction-associated steatohepatitis (MASH)
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for miricorilant in metabolic dysfunction-associated steatohepatitis (MASH) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Results from our Phase 2b MONARCH study, with results expected by the end of this year”